Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ejphar.2007.07.027
DC FieldValue
dc.titleCysteinyl leukotriene receptor antagonist MK-571 alters bronchoalveolar lavage fluid proteome in a mouse asthma model
dc.contributor.authorWong, W.S.F.
dc.contributor.authorZhu, H.
dc.contributor.authorLiao, W.
dc.date.accessioned2011-09-29T05:55:00Z
dc.date.available2011-09-29T05:55:00Z
dc.date.issued2007
dc.identifier.citationWong, W.S.F., Zhu, H., Liao, W. (2007). Cysteinyl leukotriene receptor antagonist MK-571 alters bronchoalveolar lavage fluid proteome in a mouse asthma model. European Journal of Pharmacology 575 (1-3) : 134-141. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejphar.2007.07.027
dc.identifier.issn00142999
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/27313
dc.description.abstractCysteinyl leukotriene receptor type 1 (leukotriene CysLT1 receptor) antagonist is one of the most effective anti-inflammatory agents for asthma. The spectrum of protein targets that can be regulated by leukotriene CysLT1 receptor antagonist in asthma is not fully understood. The present study tried to identify novel protein targets of a selective leukotriene CysLT1 receptor antagonist MK-571 in allergic airway inflammation by analyzing the proteome of mouse bronchoalveolar lavage fluid. BALB/c mice sensitized and challenged with ovalbumin showed increased pulmonary inflammatory cell infiltration, airway mucus production and serum ovalbumin-specific IgE level. MK-571 inhibited all these allergic airway inflammation endpoints. Lavage fluid proteins were resolved by two-dimensional gel electrophoresis and identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The level of fourteen bronchoalveolar lavage fluid protein spots was markedly altered by MK-571. A family of chitinases (Ym1, Ym2 and acidic mammalian chitinase), lungkine, surfactant protein-D and γ-actin have been found for the first time to be down-regulated by leukotriene CysLT1 receptor antagonist in mouse allergic airways. Some of the down-regulatory effects were confirmed with reverse transcription-polymerase chain reaction analyses. Taken together, we have identified novel protein targets that can be regulated by leukotriene CysLT1 receptor antagonist in mouse allergic airway inflammation, and our findings reveal additional pharmacological actions of leukotriene CysLT1 receptor antagonist in the treatment of asthma. © 2007 Elsevier B.V. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ejphar.2007.07.027
dc.sourceScopus
dc.subjectChitinase
dc.subjectLungkine
dc.subjectOvalbumin
dc.subjectProteomics
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1016/j.ejphar.2007.07.027
dc.description.sourcetitleEuropean Journal of Pharmacology
dc.description.volume575
dc.description.issue1-3
dc.description.page134-141
dc.identifier.isiut000250801100019
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

13
checked on Sep 27, 2022

WEB OF SCIENCETM
Citations

12
checked on Sep 27, 2022

Page view(s)

383
checked on Sep 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.